Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Phase 1

Suspended

• Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma
• Interventions: Drug: Bevacizumab and Carboplatin

• Registration Number: NCT01386710
• Lead Sponsor: Northwell Health

Brief Summary

The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of either surgical resection, external beam radiation or both. All patients experience a recurrence after first-line therapy, so improvements in both first-line and salvage therapy are critical to enhancing quality-of-life and prolonging survival. It is unknown if currently used intravenous (IV) therapies even cross the blood brain barrier (BBB). The investigators have shown in a previous phase I trial that a single Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (up to 15mg/kg) is safe and effective in the treatment of recurrent GBM. Therefore, this phase I/II clinical research trial is an extension of that trial in that the investigators seek to test the hypothesis that repeated dosing of intra-arterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma. Additionally the investigators will analyze if a combination with IA Carboplatin will further improve the treatment response. By achieving the aims of this study the investigators will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival. The investigators expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for malignant glioma, and may alter the way these drugs are delivered to the investigators patients in the near future.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-06-13
• Study First Submitted QC: 2011-06-29
• Study First Posted: 2011-07-01
• Study Start: 2011-09
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-05
• Last Update Posted: 2025-04-09
• Primary Completion: 2026-12
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

• 18 years of age or older.
• Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA).
• Circumscribed tumor recurrence with less than 3.5 cm greatest diameter
• Patients with histologically confirmed low-grade brain tumor relapse with an enhancing tumor on MRI will be evaluated for toxicity only.
• Patients must have at least one confirmed and evaluable tumor site.
• Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level of 0-2)
• Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period.

Exclusion Criteria

• Women who are pregnant or lactating.
• Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.
• Low GFR or history of hepatorenal syndrome

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 2	Bevacizumab and Carboplatin	Drug: Bevacizumab and Carboplatin
Arm 1	Bevacizumab and Carboplatin	Drug: Bevacizumab and Carboplatin

Primary Outcome Measures

Name	Time	Method
Composite overall response rate	6 months	The composite overall response rate (CORR) will be examined. The overall response proportion along with a 95% confidence interval will be estimated via binomial proportions.
Six-month progression-free survival (PFS) and overall survival (OS)	2 years	PFS will be measured from the date of the first dose of SIACI Bevacizumab plus Carboplatin to the date of progression. OS will be measured from the date of the first dose of SIACI Bevacizumab plus Carboplatin to the date of death.

Secondary Outcome Measures

Name	Time	Method
The safety of repeated SIACI of Mannitol, Bevacizumab plus Carboplatin at 15mg/kg and 150mg/m2 respectively.	1 month	The descriptive frequency of subjects experiencing toxicities will also be tabulated. Toxicities will be assessed and graded according to the NCI Common Toxicity Criteria, version 3.0.

Trial Locations

Locations (1)

Lenox Hill Brain Tumor Center; 🇺🇸 New York, New York, United States